Skip to main content

Table 1 Probability parameters

From: Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults

Events

Splenectomy

Romiplostim

Rituximab

Corticosteroids

Efficacy rates

76.1% [15]

84.1% [14]

71.6% [16,17]

Relapse rates

0.45% [3]

0%*

0.88% [18]

Adverse event rates

0.44% [13]

0.58% [14]

0.24% [7]

11% [19]

Emergency treatment rates (PL < 30 × 109/L)

14.4% [20]

14.4% [20]

14.4% [20]

26.8% [20]

Emergency treatment rates (PL ≥ 30 × 109/L)

0.4% [20]

0.4% [20]

0.4% [20]

Mortality rate (PL < 30 × 109/L)

GR (%) × 4.2 + 0.02%[1,3,21]

GR (%) × 4.2 [1,21]

GR (%) × 4.2 [1,21]

GR (%) × 4.2 [1,21]

Mortality rate (PL ≥ 30 × 109/L)

GR (%) × 1.8 [1,21]

GR (%) × 1.8 [1,21]

GR (%) × 1.8 [1,21]

GR (%) × 1.8 [1,21]

  1. PL: platelet, GR: General mortality rate. References are given in brackets.
  2. *If romiplostim treatment is effective, then relapse would not occur.
  3. A mortality rate of 0.02% was added when splenectomy was conducted.